Single-Cell Analysis Market is expected to reach US$ 8.20 billion by 2028


PRESS RELEASE BY The Insight Partners 29 Sep 2022

Share this press on


Growing Prevalence of Cancer and Rising Funding Support Likely to Catalyze Single-Cell Analysis Market During Forecast Period

According to our latest market study on "Single-cell analysis Market Forecast to 2028 – COVID-19 Impact and Global Analysis – by Product, Cell Type, Technique, Application, End User, and Geography," the market is expected to grow from US$ 3.18 billion in 2021 to US$ 8.20 billion by 2028; it is projected to grow at a CAGR of 14.5% from 2022 to 2028.

Single-Cell Analysis Market


Single-Cell Analysis Market Size and Forecasts (2021 - 2031), Global and Regional Share, Trends, and Growth Opportunity Analysis

Download Free Sample

Single-Cell Analysis Market Size and Forecasts (2021 - 2031), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: by Product (Consumables and Instruments), Cell Type (Human Cells, Animal Cells, and Microbial Cells), Technique (Flow Cytometry, Next-Generation Sequencing, Polymerase Chain Reaction, Microscopy, Mass Spectrometry, and Other Techniques), Application (Research Applications and Medical Applications), and End User (Academic and Research Laboratories, Biotechnology and Pharmaceutical Companies, Hospitals and Diagnostic Laboratories, and Cell Banks and IVF Centers), and Geography (North America, Europe, Asia Pacific, and South and Central America)

Source: The Insight Partners Analysis

Cancer cases is one of the major causes of death across the world and its burden is set to spiral. According to the National Cancer Institute, 1,806,590 new cancer cases were reported in the US and 606,520 associated deaths (mortalities) were registered in 2020. According to World Health Organization (WHO), around 10 million deaths were caused by cancer in 2020 worldwide. International Agency for Research on Cancer (IARC) stated that by 2040, the global burden of cancers is expected to grow to 27.5 million new cancer cases and 16.3 million deaths worldwide. Growing diagnosis and treatment seeking rate are likely to enable the monitoring and management of cancer progression. Single-cell analysis utilize automated workflows with real-time monitoring of cancer cells and create novel therapeutic strategies for clinical management. This is expected to lead to more efficient and better analysis. Therefore, increasing incidence of cancer will boost R&D activities, further acting as one of the major driving factors to the market.

Based on product, the single-cell analysis market is bifurcated into instruments and consumables. In 2021, consumables accounted for the largest share of the single-cell analysis market due to their high consumption than instruments.

By technique, the market is segmented into flow cytometry, next-generation sequencing, polymerase chain reaction, microscopy, mass spectrometry, and other techniques. The next-generation sequencing segment accounted for the largest market share in 2021, and it is expected to dominate the market over the forecast period owing to increasing adoption in genome mapping program and technological advancement in sequencing platform.

The end user segment is further segmented into academic and research laboratories, biotechnology and pharmaceutical companies, hospitals and diagnostic laboratories, and cell banks and IVF centers. The academic and research laboratories segment accounted for the largest market share in 2021, and it is expected to continue its dominance in the market over the forecast period. A rise in R&D activities coupled with public–private funding and growing number of academic and research laboratories facilities are expected to support the growth of the single-cell analysis market.

North America dominated the single-cell analysis market with ~42% market share in 2021. The market growth in the region is majorly attributed to increasing R&D expenditure and government funding, well-developed healthcare infrastructure, growing pharmaceutical and life science industry, and strategic initiatives by prominent players along with the existence of these major players in the region. Moreover, rising awareness due to the high incidence of cancer diseases in the region has stimulated the growth of single-cell analysis market. Further, there has been a surge in COVID-19-related research projects, especially after the outbreak, using single-cell genome sequencing, consequently driving market expansion. Thus, owing to the above-mentioned factors, the single-cell analysis market is expected to witness significant growth over the forecast period in North America.

Agilent Technologies; Beckman Coulter Inc.; Becton Dickinson & Company (BD); Bio-Rad Laboratories, Inc.; Fluidigm Corporation; GE Healthcare; Illumina, Inc.; Merck KGaA; Qiagen N.V.; and Thermo Fisher Scientific, Inc. are among the key players profiled during the study of the single-cell analysis market. Several other major companies were analyzed during this study to get a holistic view of the single-cell analysis market and its ecosystem.

Contact Us
 
Phone: +1-646-491-9876
Email Id: sales@theinsightpartners.com

Download Free PDF Brochure